All the Therapeutic System Drugs
Monoclonal Antibody. Reslizumab 10 mg/ml. VIAL(Concent. for sol. for infus.): 1×10ml, 100ml. IV infus. only. Do not admin. as an IV push or bolus. The recomm. regimen is 3 mg/kg once every 4 wks. admin. by IV infus. over 20-50 min. Discont. the infus. immed. if the pt. experience. a sev. syst. react., including anaphylaxis.
Indic. for the add-on mainten. tmt. of pts. with sev. asthma aged 18 yrs. and older with an eosinophilic phenotype.
C/I: Hypersens.
Corticosteroid. Fluticasone Propionate 0.5 mg / 2 ml, 2 mg/ 2 ml. AMPS FOR NEBULIZAT: 2 ml x 0.5 mg, 2
mg. 500 μg-2,000 μg 2 x dly, adjust.
dose as reqd. Child and adolesc. from
4-16 yrs: 1,000 μg 2 x dly.
Proph. severe asth., tmt. acute exacerb.
asth. in adults, child. and adolesc. 4-16 yrs
and over.
Corticosteroid/Beta 2-Agonist. Beclometasone Dipropionate 200mcg/metered dose, Formoterol Fumarate 6mcg/metered dose. INHALER. (Pressurised sol. for inhal).:1×120 actuation.
Adults 18 yrs. and above:
Two inhalations twice dly.
The max. dly. dose is 4 inhalat.
Foster 200/6 should be used as mainten. therapy only. A lower strength (Foster 100/6) is available for mainten. and reliever ther.
Indicated in the regular tmt. of asthma in adult. where use of a comb. product (inhaled corticosteroid and long-act. Β2-ag.) is appropriate:
Pts. not adequate. control. with inhaled corticosteroids and 'as needed' inhaled rapid-acting Β2-agonist.
Pts. already adequat. controlled on both inhaled corticosteroids and long-act. Β2-ag. C/I: Hypersens.
Leukotriene Receptor Antagonist. Montelukast Sodium 4mg, 5mg. Chew. Tabs.: 30. Adlt. 15 years and over with Asthma and/or Season. allergic rhinitis: 10 mg /d.
Ped. pts. 6 to 14 years old with Asthma and/or Season. allergic rhinitis: 5 mg/d. Ped. pts. 2 to 5 years old with Asthma and/or Season. allergic rhinitis: 4-mg/d.
Tabs 4 mg. in adlt. and ped. pts. aged 2 and over for the prophyl. and chron. tmt. of asthma, incl. prevent. of daytime and nighttime sympt., tmt. of aspirin-sensit. asthmatic pts., and prevent. of exercise-induced bronchoconstrict. Effect. alone or in comb. with other agents used in the maint. tmt of chronic asthma. This drug and inh. corticost. may be used concom. with addit. effects to ctrol. asthma or reduce. the inhal. corticost. dose while maintaining clin. stability. For the relief of sympt. of season. allergic rhinitis in adlts and ped. pts. aged and over.
Tabs 5mg. for use by adlt. and ped. pts. aged 6 and over.
C/I:hypersens
Leukotriene Receptor Antagonist. Montelukast Sodium 4 mg, 5 mg, 10 mg. Montelukast as sod. salt.
CHEW TABS: 28 x 4 mg,/ 5 mg.
TABS: 28 x 10 mg .
adult. 15 yrs. and older: 1 tab. 10mg dly.
child. 6-14 yrs.:1 chew. tab. 5 mg dly.
child.2-5 yrs.: 1 chew. tab. 4 mg dly.
Proph./chron. tmt. asthma in adult/child.
incl. prevent. of day/night sympts.
Tmt. of aspirin sens. asthmatic pts., prevent.of
exercise-induced bronchoconstrict,.
may be used alone or as a combin.
with other agents. For the relief of
sympts. seasonal allergic rhinitis in
adults and child. Not for use of child. under2 yrs old.
C/I:hypersens.
Monoclonal Antibody. Mepolizumab 100 mg. VIAL: 1 or 3 X 100 mg Pre-filled pen: 1 or 3 X 1ml
100 mg SC once every 4 weeks.
Limitations for COPD: may be used in pts with an eosinophil level above 150 cells/μL.
Sev. eosinophilic asthma :as add-on for sev. refract. eosinophilic asthma in adlts. Chron. rhinosinusitis with nasal polyps (CRSwNP):as add-on with intranasal corticost. for adlts with sev. CRSwNP for whom ther. with corticost. and surgery in the last 10 years do not provide adeq. dis. ctrol. Eosinophilic Granulomatosis with Polyangiitis (EGPA): for adlts with eosinophilic granulomatosis with polyangiitis (EGPA). Hypereosinophilic syndrome (HES) :as add-on for adlts with inadeq. ctrolled hypereosinophilic syndr. w/o an identifiable non-haematologic second. Cause
Pre-filled pen- Chron. obstructive pulm. disease (COPD): as add-on maint. tmt of adlts with inadeq. ctrolled chron. obstructive pulm. dis. with an eosinophilic phenotype.
C/I: Hypersens.
